851228-89-2

Upstream product

• 80922-14-1 1-nitro-4-phenylbut-1-ene 
• 104-53-0 3-phenyl-propionaldehyde 
• 851228-88-1 C₄₅H₇₅NO₃Si₂ 
• 80-62-6 methacrylic acid methyl ester 
• 151919-93-6 (5Z,7E,20R)-1α,3β-bis(tert-butyldimethylsilyloxy)-20-cyanomethyl-9,10-seco-5,7,10(19)-pregnatriene 
• 143884-26-8 (5Z,7E,20R)-1α,3β-bis<(tert-butyldimethylsilyl)oxy>-20-formylmethyl-9,10-seco-5,7,10(19)-pregnatriene 
• 141377-53-9 1-nitro-4-phenylbutan-2-ol 
• 114694-12-1 (5Z,7E)-(1S,3R,20S)-1,3-bis<(tert-butyldimethylsilyl)oxy>-9,10-seco-22,23-dinor-5,7,10(19)-cholatrien-24-ol 
• 114694-13-2 (5Z,7E)-(1S,3R,20S)-1,3-bis<(tert-butyldimethylsilyl)oxy>-9,10-seco-22,23-dinor-5,7,10(19)-cholatrienol 22-p-toluenesulfonate 
• 851228-77-8 4-phenylbutylhydroxylamine 

Relevant academic research and scientific papers

Practical synthesis and evaluation of the biological activities of 1α,25-dihydroxyvitamin D3 antagonists, 1α,25- dihydroxyvitamin D3-26,23-lactams. Designed on the basis of the helix 12-folding inhibition hypothesis

A practical synthetic route to novel vitamin D antagonists of DLAM (1α,25-dihydroxyvitamin D3-26,23-lactam) was developed from vitamin D2 via the 1,3-dipolar cycloaddition reaction as a key step. Six DLAM derivatives (24 compounds) w

Vitamin D3 lactam derivative

Compounds expressed by the following formula (1) or pharmaceutically permissible solvate thereof which is effective for treating Paget's disease of bone, hypercalcemia or osteoporosis. In the formula, R1 is a C2-C10 alkyl